A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

One of the most relevant targets in the field of novel targeted anticancer therapy is the family of receptors to fibroblast growth factor receptors (FGFRs). FGFR1 is the main representative of the FGFR family. The goal of this clinical trial is to learn if monoclonal anti-FGFR1 antibody (OM-RCA-01) works to treat metastatic cancers expressing FGFR1. It will also learn about the safety of drug OM-RCA-01. The main questions it aims to answer are: 1. What medical problems do participants have when receiving drug OM-RCA-01? 2. What dose of the drug should patients receive in the next studies? 3.

Trial Details

NCT ID

NCT07292168

Phase

PHASE1 / PHASE2

Sponsor

Kidney Cancer Research Bureau

Status

RECRUITING

Cancer Type

Kidney Cancer

Interventions

humanized monoclonal anti-FGFR1 antibody OM-RCA-01

Locations (sample)

Kazan', Russia|55.78874,49.12214
Krasnoyarsk, Russia|56.03742,92.93136
Moscow, Russia|55.75204,37.61781
Saint Petersburg, Russia|59.93863,30.31413
Ufa, Russia|54.74306,55.96779

Key Eligibility Criteria

Signed and dated Informed Consent Form confirming voluntary participation in the study.
Age ≥ 18 years at the time of consent.
Body weight ≥ 50 kg.
Histologically confirmed metastatic solid tumors:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →